Washington, D.C. Partner David Rosen was quoted in an Inside Health Reform article on July 17, 2013 titled, “FDA Legal Action Holds N.J. Compounder to Manufacturing Standards.” The article discusses a recent consent decree of permanent injunction against a drug compounder that FDA previously flagged mandates the pharmacy follow drug manufacturer standards. Mr. Rosen was quoted saying, “They’re holding them to drug manufacturer-style GMPs.” He also noted that drug companies involved in consent decrees sometimes enter a plan to rehab some of their products, whether it be active pharmaceutical ingredients or ingredients in process, but this must be approved by FDA and there is often a bond to ensure it is carried out.
People
Related News
December 3, 2025
In the News
Vanessa Miller Assesses Automotive Tariff Impact on Trucking Industry
Foley & Lardner LLP partner Vanessa Miller discussed the ongoing disruption in trucking demand resulting from recent automotive tariffs in the TruckingDive article, “Tariffs swing volumes up and down for auto haulers.”
November 28, 2025
In the News
Cassandra Aubert Assesses Circuit Split on SEC Disgorgement Authority
Foley & Lardner LLP associate Cassandra Aubert commented on the growing scrutiny around the U.S. Security and Exchange Commission's disgorgement authority in the Bloomberg Law's article, “SEC Power to Recoup Illegal Profits at Risk as Justices Eye Case."
November 25, 2025
In the News
Gregory Husisian Analyzes SCOTUS Tariff Case
Foley & Lardner LLP partner Gregory Husisian appeared in a SupplyChainBrain video interview to discuss the U.S. Supreme Court case on the Trump administration’s imposition of tariffs under the International Emergency Economic Powers Act (IEEPA) and options the administration can consider should the court strike them down.